Liposomal nanomedicine for breast cancer therapy

Nanomedicine

Volumn 6, Issue 6, 2011, Pages 1085-1100

  Paliwal, Shivani Rai ^a   Paliwal, Rishi ^a   Agrawal, Govind P ^a   Vyas, Suresh P ^a  

^a DR H S GOUR UNIVERSITY   (India)

Author keywords

anticancer drug; breast cancer; gene therapy; liposomes; molecular targets

Indexed keywords

ANGIOGENIC FACTOR; ANTINEOPLASTIC AGENT; APOPTOSIS INDUCING FACTOR; CD44V ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FOLATE RECEPTOR; HORMONE RECEPTOR; HYALURONIC ACID BINDING PROTEIN; IMMUNOLIPOSOME; INTEGRIN; MATRIX METALLOPROTEINASE; MUCIN 1; PROTEIN VP22; TRANSFERRIN RECEPTOR; VASCULOTROPIN RECEPTOR;

BREAST CANCER; CANCER CELL; CANCER THERAPY; CELL CYCLE; GENE THERAPY; HUMAN; LIPOSOMAL DELIVERY; MOLECULARLY TARGETED THERAPY; NANOMEDICINE; PH; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TEMPERATURE SENSITIVE CLONE; TUMOR;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; LIPOSOMES; NANOMEDICINE;

EID: 80052298054     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.11.72     Document Type: Review

References (136)

1. Park JW. Liposome-based drug delivery in breast cancer treatment. Breast Cancer Res. 4, 95-99 (2002). nn Describes earlier developments in the field of liposome-mediated drug delivery for breast cancer treatment.
2. Allred DC, Mohsin SK, Fuqua SA. Histological and biological evolution of human premalignant breast disease. Endocr. Relat. Cancer 8, 47-61 (2001).
3. Gabizon AA, Shiota R, Papahadjopoulos D. Pharmacokinetics and tissue distribution of doxorubicin encapsulated in stable liposomes with long circulation times. J. Natl Cancer Inst. 81, 1484-1488 (1989). n Discusses biodistribution and pharmacokinetics of anticancer agents after encapsulation in long circulatory liposome.
4. Kelsey JL. A review of the epidemiology of human breast cancer. Epidemiol. Rev. 1, 74-109 (1979).
5. Arun B, Hortobagyi GN. Progress in breast cancer chemoprevention. Endocr. Relat. Cancer 9, 15-32 (2002).
6. O'Shaughnessy J. Liposomal anthracyclines for breast cancer: Overview. Oncologist 8, 1-2 (2003).
7. Fisher B, Fisher ER, Redmond C, Brown A. Tumor nuclear grade, estrogen receptor, and progesterone receptor: Their value alone or in combination as indicators of outcome following adjuvant therapy for breast cancer. Breast Cancer Res. Treat. 7, 147-160 (1986).
8. Pietras RJ, Szego CM. Specific binding sites for oestrogen at the outer surfaces of isolated endometrial cells. Nature 265, 69-72 (1977).
9. Levine AJ. p53, the cellular gate keeper for growth and division. Cell. 88, 323-331 (1997).
10. Haussler MR, Whitfield GK, Haussler CA et al. The nuclear vitamin D receptor: Biological and molecular regulatory properties revealed. J. Bone Min. Res. 13, 325-349 (1998).
11. Ozono K, Sone T, Pike JW. Perspectives: The genomic mechanism of action of 1,25-dihydroxyvitamin D3. J. Bone Min. Res. 6, 1021-1027 (1991).
12. Brenner RV, Shabahand M, Schumaker LM et al. The antiproliferative effect of vitamin D analogs on MCF-7 human breast cancer cells. Cancer Lett. 9285, 77-82 (1995).
13. Colston KW, Berger U, Coombes RC. Possible role for vitamin D in controlling breast cancer cell proliferation. Lancet 28, 188-191 (1989).
14. Mangelsdorf DJ, Thummel C, Beato M et al. The nuclear receptor superfamily: The second decade. Cell. 83, 835-839 (1995).
15. Ariga N, Moriya T, Suzuki T, Kimura M, Ohuchi N, Sasano H. Retinoic acid receptor and retinoid X receptor in ductal carcinoma in situ and intraductal proliferative lesions of the human breast. Jap. J. Cancer Res. 91, 1169-1176 (2000).
16. Toma S, Isnardi L, Raffo P et al. Effects of all-trans-retinoic acid and 13-cis-retinoic acid on breast-cancer cell lines: Growth inhibition and apoptosis induction. Int. J. Cancer 70, 619-627 (1997).
17. Beatson GT. On the treatment of inoperable cases of carcinoma of the mamma: Suggestions for a new method of treatment, with illustrative cases. Lancet 2, 104-107 (1896).
18. Dinda S, Sanchez A, Moudgil V. Estrogen-like effects of thyroid hormone on the regulation of tumor suppressor proteins p53 and retinoblastoma, in breast cancer cells. Oncogene 21, 761-768 (2002).
19. Selliti D, Tseng Y, Latham K. Nuclear thyroid hormone receptors in C3H/HeN mouse mammary glands and spontaneous tumors. Cancer Res. 43, 1030-1038 (1983).
20. Cerbon MA, Pichon MF, Milgrom E. Thyroid hormone receptors in human breast cancer. Cancer Res. 41, 4167-4173 (1981).
21. Silva JM, Dominguez G, Gonzalez-Sancho JM et al. Expression of thyroid hormone receptor/erbA genes is altered in human breast cancer. Oncogene 21, 4307-4316 (2002).
22. Tontonoz P, Hu E, Graves RA, Budavari A, Spiegelman BM. mPPAR tissue-specific regulator of an adipocyte enhancer. Genes Dev. 8, 1224-1234 (1994).
23. Mueller EF, Sarraf P, Tontonoz P et al. Terminal differentiation of human breast cancer through PPAR. Mol. Cell 1, 465-470 (1998).
24. Schwartz MA. Integrins, oncogenes, and anchorage independence. J. Cell Biol. 139, 575-578 (1997).
25. Aaronson SA. Growth factors and cancer. Science 254, 1146-1153 (1991).
26. Bacus SS, Zelnick CR, Plowman G, Yarden Y. Expression of the erbB-2family of growth factor receptors and their ligands in breast cancers. Implication for tumor biology and clinical behavior. Am. J. Clin. Pathol. 102, S13-S24 (1994).
27. Viloria Petit AM, Rak J, Hung MC et al. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: Angiogenic implications for signal transduction therapy of solid tumors. Am. J. Pathol.. 151, 1523-1530 (1997).
28. Cobleigh MA, Vogel CL, Tripathy D et al. Multinational study of the efficacy and safety of humanized anti-HER2antibody in women who have HER2-overexpressing breast cancer that has progressed after therapy for metastatic disease. J. Clin. Oncol. 17, 2639-2648 (1999).
29. Qiu F, Ray P, Brown K et al. Primary structure of c-kit: Relationship with the CSF-1/PDGF receptor kinase family-oncogenic activation of v-kit involves deletion of extracellular domain and C terminus. EMBO J. 7, 1003-1011 (1988).
30. Matsuda R, Takahashi T, Nakamura S et al. Expression of the c-kit protein in human solid tumors and in corresponding fetal and adult normal tissues. Am. J. Pathol. 142, 339-346 (1993).
31. Natali P, Nicotra M, Sures I, Mottolese M, Botti C, Ullrich A. Breast cancer is associated with loss of the c-kit oncogene product. Int. J. Cancer 52, 713-717 (1992).
32. DiPaola RS, Kuczynski W, Onodera K et al. Evidence for a functional kit receptor in melanoma, breast, and lung carcinoma cells. Cancer Gene Ther. 4, 176-182 (1997).
33. Lokker NA, Sullivan CM, Hollenbach SJ, Israel MA, Giese NA. Platelet-derived growth factor (PDGF) autocrine signalling regulates survival and mitogenic pathways in glioblastoma cells: Evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors. Cancer Res. 62, 3729-3735 (2002).
34. Bhardwaj B, Klassen J, Cossette N et al. Localization of platelet-derived growth factor a receptor expression in the periepithelial stroma of human breast carcinoma. Clin.Cancer Res. 2, 773-782 (1996).
35. Ariad S, Seymour L, Bezwoda WR. Platelet-derived growth factor (PDGF) in plasma of breast cancer patients: Correlation with stage and rate of regression. Breast Cancer Res Treat. 20, 11-17 (1991).
36. Valencia A, Chardin P, Wittinghofer A, Sander C. The ras protein family: Evolutionary tree and role of conserved amino acids. Biochem. 30, 4637-4648 (1991).
37. Keely PJ. Ras and Rho protein induction of motility and invasion in T47D breast adenocarcinoma cells. Methods Enzymol. 333, 256-266 (2001).
38. Kleer CG, van Golen KL, Zhang Y, Wu ZF, Rubin MA, Merajver SD. Characterization of RhoC expression in benign and malignant breast disease: A potential new marker for small breast carcinomas with metastatic ability. Am. J. Pathol. 160, 579-584 (2002).
39. Sherr C, Roberts JM. CDK inibitors: Positive and negative regulators of G1-phase progression. Genes Dev. 13, 1501-1512 (1999).
40. Chen J, Wu W, Tahir SK et al. Down-regulation of survivin by antisense oligonucleotides increases apoptosis, inhibits cytokines and anchorage-independent growth. Neoplasia 2, 235-241 (2000).
41. Adida C, Crotty PL, McGrath J, Berrebi D, Diebold J, Altieri DC. Developmentally regulated expression of the novel anti-apoptasis gene survivin in human and mouse differentiation. Am. J. Pathol. 152, 43-49 (1998).
42. Tamm I, Wang Y, Sausville E et al. IAP-family protein survivin inhibits caspases activity and apoptosis induced by fas (CD 95), Bax, and anticancer drugs. Cancer Res. 58, 5315-5320 (1998).
43. Giaccia AJ, Kastan MB. The complexity of p53 modulation: Emerging patterns from divergent signals. Genes Dev. 12, 2973-2983 (1998).
44. Asker C, Wiman KG, Selivanova G. p53-induced apoptosis as a safeguard against cancer. Biochem. Biophys. Res. Comm. 265, 1-6 (1999).
45. Pharoah PDP, Day NE, Caldas C. Somatic mutations in the p53 gene and prognosis in breast cancer: A meta-analysis. Br. J. Cancer 80, 1968-1973 (1999).
46. Elledge RM, Allred DC. Prognostic and predictive value of p53 and p21 in breast cancer. Breast Cancer Res. Treat. 52, 79-98 (1998).
47. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nature Med. 6, 389-395 (2000).
48. Yancopoulos GD, Davis S, Gale NW et al. Vascular-specific growth factors and blood vessel formation. Nature 407, 242-248 (2000).
49. Okamoto I, Tsuiki H, Kenyon LC et al. Proteolytic cleavage of the CD44 adhesion molecule in multiple human tumors. Am. J. Pathol. 160, 441-447 (2002).
50. Ullrich A, Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. Cell 61, 203-212 (1990).
51. Fox SB, Taylor M, Grondahl-Hansen J, Kakolyris S, Gatter KC, Harris AL. Plasminogen activator inhibitor-1 as a measure of vascular remodeling in breast cancer. J. Pathol. 195, 236-243 (2001).
52. Malmstrom P, Bendahl PO, Boisen P, Brunner N, Idvall I, Ferno M. S-phase fraction and urokinase plasminogen activator are better markers for distant recurrences than Nottingham Prognostic Index and histologic grade in a prospective study of premenopausal lymph node-negative breast cancer. J. Clin. Oncol. 19, 2010-2019 (2001).
53. Rabbani SA, Gladu J. Urokinase receptor antibody can reduce tumor volume and detect the presence of occult tumor metastases in vivo. Cancer Res. 62, 2390-2397 (2002).
54. Schwartz MA. Integrins, oncogenes, and anchorage independence. J. Cell Biol. 39, 575-578 (1997).
55. Lohi J. Laminin-5 in the progression of carcinomas. Int. J. Cancer 94, 763-767 (2001).
56. Seftor R, Seftor E, Sheng S, Phemberton PA, Sager R, Hendrix MJC. Maspin suppresses the invasive phenotype of human breast carcinoma. Cancer Res. 58, 5681-5685 (1998).
57. Mercurio AM, Bachelder RE, Chung J et al. Integrin laminin receptors and breast carcinoma progression. J. Mammary Gland Biol. Neoplasia 6, 299-309 (2001).
58. Rozic JH, Chakraborty C, Lala PK. Cyclooxygenase inhibitors retard murine mammary tumor progression by reducing tumor cell migration, invasiveness and angiogenesis. Int. J. Cancer 93, 497-506 (2001).
59. Rai S, Paliwal R, Vaidya B et al. Solid lipid nanoparticles (SLNs) as a rising tool in drug delivery science: One step up in nanotechnology. Curr. Nanosci. 4, 30-44 (2008).
60. Banerjee R. Liposomes: Applications in medicine. J. Biomater. Appl. 16, 3-21 (2001). nn Systematically elaborates application of liposomes in the field of medicine.
61. Bangham AD, Standish MM, Watkins JC. Diffusion of univalent ions across lamellae of swollen phospholipids. J. Mol. Biol. 13, 238-252 (1965).
62. Rooijen VN, Nieuwmegen VR. Liposomes in immunology: Multilamellar phosphatidylcholine liposome as a simple biodegradable and harmless adjuvant without any immunogenic activity of its own. Immunol. Commun. 9, 243-256 (1980).
63. Ong JC, Sun F, Chan E. Development of stealth liposome coencapsulating doxorubicin and fluoxetine. J. Lipo. Res. DOI: 10.3109/08982104.2010.545070 (2011) (Epub ahead of print).
64. Senior J, Crawleye JCW, Gregoriadis G. Tissue distribution of liposomes exhibiting long half-lives in the circulation after intravenous injection. Biochim. Biophys. Acta 839, 1-8 (1985).
65. Zalipsky S, Hansen CB, Menezes DEL, Allen TM. Longcirculating, polyethylene glycol-grafted immunoliposomes. J. Cont. Rel. 39, 153-161 (1996).
66. Sugarman SM, Perez-Soler R. Liposomes in the treatment of malignancy: A clinical perspective. Crit. Rev. Oncol. Hematol. 12, 231-242 (1992).
67. Muggia FM. Doxorubicin-polymer conjugates: Further demonstration of the concept of enhanced premeability and retention. Clin. Cancer Res. 5, 7-8 (1999).
68. Working PK, Newman MS, Sullivan T, Yarrington J. Reduction of the cardiotoxicity of doxorubicin in rabbits and dogs by encapsulation in longcirculating PEGylated liposomes. J. Pharmacol. Exp. Ther. 289, 1128-1133 (1999).
69. Gabizon AA, Shmeeda H, Horowitz AT, Zalipsky S. Tumor cell targeting of liposome-entrapped drugs with phospholipidanchored folic acid-PEG conjugates. Adv. Drug Deliv. Rev. 56, 1177-1192 (2004).
70. Goyal P, Goyal K, Kumar SGV, Singh A, Katare OP, Mishra DN. Liposomal drug delivery systems: Clinical applications. Acta Pharm. 55, 1-25 (2005).
71. Park JW, Kirpotin DB, Hong K et al. Tumor targeting using anti-HER2 immunoliposomes. J. Control. Release 74, 95-113 (2001).
72. Hung MC, Matin A, Zhang Y et al. HER-2/neu-targeting gene therapy - a review. Gene 159, 65-71 (1995).
73. Slamon DJ, Leyland-Jones B, Shak S. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783-792 (2001).
74. Noble CO, Guo Z, Hayes ME, Marks JD, Park JW, Benz CC. Characterization of highly stable liposomal and immunoliposomal formulations of vincristine and vinblastine. Cancer Chemother. Pharmacol. 64, 741-751 (2009). n Demonstrates development of monoclonal antibody-targeted liposome containing chemotherapeutic agents.
75. Anderson RG, Kamen BA, Rothberg KG, Lacey SW. Potocytosis: Sequestration and transport of small molecules by caveolae. Science 255, 410-411 (1992).
76. Goren D, Horowitz AT, Tzemach D, Tarshish M, Zalipsky S, Gabizon A. Nuclear delivery of DOX via folate targeted liposomes with bypass of multidrug-resistance efflux. Clin. Cancer Res. 6, 1949-1957 (2000).
77. Rait AS, Kathleen KF, Xiang L, Ulick D, Chang EH. Tumor-targeting, systemically delivered antisense HER-2 chemosensitizes human breast cancer xenografts irrespective of HER-2 levels. Mol. Med. 8, 475-486 (2002).
78. Osborne CK. Steroid hormone receptors in breast cancer management. Breast Cancer Res. Treat. 51, 227-238 (1998).
79. Rai S, Paliwal R, Vaidya B et al. Targeted delivery of DOX via estrone-appended Liposomes. J. Drug Target. 16, 455-463 (2008).
80. Rai S, Paliwal R, Vaidya B et al. Estrogen(s) and analogs as a non-immunogenic endogenous ligand in targeted drug/DNA delivery. Curr. Med. Chem. 14, 2095-2109 (2007). nn Role of estrogen receptors for targeted delivery of bioactive molecules, which may act as potential ligand for breast cancer therapy, are well presented.
81. Paliwal SR, Paliwal R, Mishra N, Mehta A, Vyas SP. A novel cancer targeting approach based on estrone anchored stealth liposome for site-specific breast cancer therapy. Curr. Cancer Drug target.10, 343-353 (2010).
82. Xiong XB, Huang Y, Lu WL, Zhang H, Zhang X, Zhang Q. Enhanced intracellular uptake of sterically stabilized liposomal DOX in vitro resulting in improved antitumor activity in vivo. Pharm. Res. 22, 933-939 (2005).
83. Jiang J, Yang SJ, Wang JC, Yang LJ, Xu ZZ, Yang T, Liu XY, Zhang Q. Sequential treatment of drug-resistant tumors with RGD-modified liposomes containing siRNA or doxorubicin. Eur. J. Pharm. Biopharm. 76, 170-178 (2010).
84. Ishida O, Maruyama K, Tanahashi H et al.; Liposomes bearing polyethyleneglycol-coupled transferrin with intracellular targeting property to the solid tumors in vivo. Pharm. Res. 18, 1042-1048 (2001).
85. Wu J, Lu Y, Lee A et al. Reversal of multidrug resistance by transferrin-conjugated liposomes co-encapsulating DOX and verapamil. J. Pharm. Sci. 10, 350-357 (2007).
86. Litvinov SV, Hilkens J. The epithelial sialomucin, episialin, is sialylated during recycling. J. Biol. Chem. 268, 21364-21371 (1993).
87. Moase EH, Qi W, Ishida T et al. Anti-MUC-1 immunoliposomal doxorubicin in the treatment of murine models of metastatic breast cancer. Biochim. Biophys. Acta 1510, 43-55 (2001).
88. Sternlicht MD, Lochter A, Sympson CJ et al. The stromal proteinase MMP3/stromelysin-1 promotes mammary carcinogenesis. Cell. 98,137-146 (1999).
89. Hatakeyama H, Akita H, Ishida E et al. Tumor targeting of doxorubicin by anti-MT1-MMP antibody-modified PEG liposomes. Int. J. Pharm. 342, 194-200 (2007).
90. Waterhouse DN, Dragowska WH, Gelmon KA, Mayer LD, Bally MB. Pharmacodynamic behavior of liposomal antisense oligonucleotides targeting Her-2/neu and vascular endothelial growth factor in an ascitic MDA435/LCC6 human breast cancer model. Cancer Biol. Ther. 3, 197-204 (2004).
91. Li L, Wartchow CA, Danthi SN, Shen Z et al. A novel antiangiogenesis therapy using an integrin antagonist or anti-Flk-1 antibody coated 90Y-labeled nanoparticles. Int. J. Radiat. Oncol. Biol. Phys. 58, 1215-1227 (2004).
92. Sherman L, Sleeman J, Herrlich P, Ponta H. Hyaluronate receptors: Key players in growth, differentiation, migration and tumor progression. Curr. Opin. Cell Biol. 6, 726-733 (1994).
93. Huang S, New L, Pan Z, Han J, Nemerow GR. Urokinase plasminogen activator/urokinase-specific surface receptor expression and matrix invasion by breast cancer cells requires constitutive p38alpha mitogen-activated protein kinase activity. J. Biol. Chem. 275, 12266-12272 (2000).
94. Herrera-Gayol A, Jothy S. Effect of hyaluronan on xenotransplanted breast cancer. Exp. Mol. Pathol. 72, 179-185 (2002).
95. Hua Q, Knudson CB, Knudson W. Internalization of hyaluronan by chondrocytes occurs via receptor-mediated endocytosis. J. Cell Sci. 106, 365-375 (1993).
96. Day AJ, Prestwich GD. Hyaluronan-binding proteins: Tying up the giant. J. Biol. Chem. 277, 4585-4588 (2002).
97. Abney JR, Braun J, Owicki JC. Lateral interactions among membrane proteins. Implications for the organization of gap junctions. Biophys. J. 52, 441-454 (1987).
98. Eliaz RE, Szoka FC Jr. Liposome-encapsulated doxorubicin targeted to CD44: A strategy to kill CD44-overexpressing tumor cells. Cancer Res. 61, 2592-2601 (2001).
99. Yatvin MB, Weinstein JN, Dennis WH, Blumenthal R. Design of liposomes for enhanced local release of drugs by hyperthermia. Science 202, 1290-1293 (1978).
100. Mills JK, Needham D. The materials engineering of temperature-sensitive liposomes. Methods Enzymol. 387, 82-113 (2004).
101. Leopold KA, Dewhirst MW, Samulski TV et al. Relationship among tumor temperature, treatment time, and histopathological outcome using preoperative hyperthermia with radiation in soft tissue sarcomas. Int. J. Radiat. Oncol. Biol. Phys. 22, 989-998 (1992).
102. Hauck ML, Dewhirst MW, Bigner DD, Zalutsky ML. Local hyperthermia improves uptake of a chimeric monoclonal antibody in a subcutaneous xenograft model. Clin. Cancer Res. 3, 63-70 (1997).
103. Gerweck LE, Seetharaman K. Cellular pH gradient in tumor versus normal tissue: Potential exploitation for the treatment of cancer. Cancer Res. 56, 1194-1198 (1996).
104. Straubinger RM, Duzgunes N, Papahadjopoulos D. pH-sensitive liposomes mediate cytoplasmic delivery of encapsulated macromolecules. FEBS Lett. 179, 148-154 (1985). nn Describes the mechanism of intracellular delivery of macromolecules using pH-sensitive liposomes.
105. Torchilin VP, Zhou F, Huang L. pH-sensitive liposomes. J. Liposome Res. 3, 201-205 (1993).
106. Budker V, Gurevich V, Hagstrom JE, Bortzov F, Wolff JA. pH sensitive, cationic liposomes: A new synthetic virus-like vector. Nat. Biotechnol. 14, 760-764 (1996).
107. Legendre JY, Szoka FC Jr. Delivery of plasmid DNA into mammalian cell lines using pH-sensitive liposomes: Comparison with cationic liposomes. Pharm. Res. 9, 1235-1242 (1992).
108. Harel YE, Kato Y. Intracellular delivery of nanocarriers for cancer therapy. Curr. Nanosci. 3, 329-338 (2007).
109. Karve S, Alaouie A, Zhou Y, Rotolo J, Sofou S. The use of pH-triggered leaky heterogeneities on rigid lipid bilayers to improve intracellular trafficking and therapeutic potential of targeted liposomal immunochemotherapy. Biomaterials. 30, 6055-6064 (2009).
110. Kaneda Y, Iwai K, Uchida T. Increased expression of DNA cointroduced with nuclear protein in adult rat liver. Science 243, 375-378 (1989).
111. Thierry AR, Dritschilo A. Intracellular availability of unmodified, phosphorothioated and liposomally encapsulated oligodeoxynucleotides for antisense activity. Nucleic Acids Res. 20, 5691-5698 (1992).
112. Alino SF, Bobadilla M, Crespo J, Lejarreta M. Human a1-antitrypsin gene transfer to in vivo mouse hepatocytes. Hum. Gene Ther. 7, 531-536 (1996).
113. Crystal RG. Transfer of genes to humans: Early lesions and obstacles to success. Science 270, 404-410 (1995).
114. Sharma A, Sharma US. Liposomes in drug delivery: Progress and limitations. Int. J. Pharm. 154, 123-140 (1997).
115. Zou Y, Zong G, Ling YH, Perez-Soler R. Development of cationic liposome formulations for intratracheal gene therapy of early lung cancer. Cancer Gene. Ther. 7, 683-696 (2000).
116. Feldman AL, Libutti SK. Progress in antiangiogenic gene therapy. Cancer. 89, 1181-1194 (2000).
117. Chen QR, Kuma D, Stass SA, Mixson AJ. Liposomes complexed to plasmids encoding angiostatin and endostatin inhibit breast cancer in nude mice. Cancer Res. 59, 3308-3312 (1999). n Liposome-mediated gene delivery for breast cancer therapy has been tested and described in this article.
118. Lesoon-Wood LA, Kim WH, Kleinman HK, Weintraub BD, Mixson AJ. Systemic gene therapy with p53 reduces growth and metastases of a malignant human breast cancer in nude mice. Hum. Gene Ther. 6, 395-405 (1995).
119. Xu L, Tang WH, Huang CC, Alexander W, Xiang LM, Pirollo KF. Systemic p53 gene therapy of cancer with immunolipoplexes targeted by anti-transferrin receptor scFv. Mol. Med. 7, 726-738 (2001).
120. Xu L, Huang C, Huang W, Tang WH, Rait A, Yin YZ. Systemic tumor-targeted gene delivery by anti-transferrin receptor scFv-immunoliposomes. Mol. Cancer Therap. 1, 337-346 (2002).
121. Yan DH, Chang LS, Hung MC. Repressed expression of the HER-2/c-erbB-2 proto-oncogene by the adenovirus E1A gene products. Oncogene 6, 343-345 (1991).
122. Yoo GH, Hung MC, Lopez-Berestein G, LaFollette S, Ensley JF, Carey M. Phase I trial of intratumoral liposome E1A gene therapy in patients with recurrent breast and head and neck cancer. Clin. Cancer Res. 7, 1237-1245 (2001).
123. Mukherjee A, Prasad TK, Rao NM, Banerjee R. Haloperidol-associated stealth liposomes: A potent carrier for delivering genes to human breast cancer cells. J. Biol. Chem. 280, 15619-15627 (2005).
124. Reddy BS, Banerjee R. 17b-Estradiol-associated stealth-liposomal delivery of anticancer gene to breast cancer cells. Angew Chem. Int. Ed. 44, 6723-6727 (2005).
125. Mahato RI. Water insoluble and soluble lipids for gene delivery. Adv. Drug Deliv. Rev. 57, 699-712 (2005).
126. Burks SR, Macedo LF, Barth ED et al. Anti-HER2 immunoliposomes for selective delivery of electron paramagnetic resonance imaging probes to HER2-overexpressing breast tumor cells. Breast Cancer Res. Treat. 124, 121-131 (2010).
127. Nicholson RI, McClelland RA, Gee JMW. Steroid hormone receptors and their clinical significance in cancer. J. Clin. Path. 48, 890-895 (1995).
128. Esteva FJ, Glaspy JA, Baidas S et al. Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer. Proc. Am. Soc. Clin. Oncol. 21, 51 (2002).
129. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol. Hemat. 19, 183-232 (1995).
130. Arteaga CL, Moulder SL, Yakes FM. HER (erbB) tyrosine kinase inhibitors in the treatment of breast cancer. Semin. Oncol. 29, 4-10 (2002).
131. Shawver LK, Lipson KE, Fong TAT, McMahon G, Plowman GD, Strawn LM. Receptor tyrosine kinases as targets for inhibition of angiogenesis. Drug. Discov. Today. 2, 50-63 (1997).
132. Oastman A, Heldin CH. Involvement of platelet-derived growth factor in disease: Development of specific antagonists. Adv. Cancer. Res. 80, (2001).
133. Lafrenie RM, Yamada KM. Integrin-dependent signal transduction. J. Cell Bioch. 61, 543-553 (1996).
134. Hatakeyama H, Akita H, Ishida E. Tumor targeting of doxorubicin by anti-MT1-MMP antibody-modified PEG liposomes. Int. J. Pharm. 342, 194-200 (2007).
135. Slimani H, Guenin E, Briane D et al. Lipopeptide-based liposomes for DNA delivery into cells expressing neuropilin-1. J. Drug Target. 14, 694-706 (2006).
136. Surace C, Arpicco S, Dufay-Wojcicki A et al. Lipoplexes targeting the CD44 hyaluronic acid receptor for efficient transfection of breast cancer cells. Mol. Pharm. 6, 1062-1073 (2009).